BIOMAT Database Logo BIOMAT Database Logo

[Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) in patients receiving chemotherapy--phase I study]. 1989

H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Dept. of Clinical Oncology, Cancer Institute Hospital.

Seventeen patients with advanced malignancy were treated with recombinant human granulocyte colony stimulating factor rhG-CSF (KRN 8601) infused intravenously over a period of 30 minutes once daily at the dose level/25 micrograms, 50 micrograms, 100 micrograms, 200 micrograms, 400 micrograms, 800 micrograms/m2 for 14 consecutive days, and the effect was compared to the period without rhG-CSF treatment. The maximum numbers of peripheral leukocyte (granulocyte) showed a dose-related increase and the nadir of leukocyte counts escalated with shortening of the period. After stopping infusion, the neutrophil count dropped to the base line level within two or three days. RhG-CSF did not affect other components of peripheral blood such as monocyte, lymphocyte, eosinophil, and hemoglobin value and platelet counts. Transient bone pain occurred in two patients receiving a dose of 800 micrograms/m2. The biochemical changes detected were increased total alkaline phosphatase activity in serum, which appeared in parallel with the increase of neutrophil numbers, and less elevation of total uric acid values. We conclude that an optimal dose of rhG-CSF is 100 micrograms/m2 (average maximum peripheral granulocyte count, 10799/microliters; nadir granulocyte count, 3772/microliters; period of neutropenia, 2.6 days), and rhG-CSF is useful for acceleration of neutrophil recovery and prevention of infection from chemotherapy.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D003115 Colony-Stimulating Factors Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF). MGI-1,Macrophage-Granulocyte Inducer,Colony Stimulating Factor,Colony-Stimulating Factor,MGI-1 Protein,Myeloid Cell-Growth Inducer,Protein Inducer MGI,Cell-Growth Inducer, Myeloid,Colony Stimulating Factors,Inducer, Macrophage-Granulocyte,Inducer, Myeloid Cell-Growth,MGI 1 Protein,MGI, Protein Inducer,Macrophage Granulocyte Inducer,Myeloid Cell Growth Inducer
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
April 1992, The Journal of urology,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets.
July 1992, Annals of hematology,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
[Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
May 1994, Zhonghua zhong liu za zhi [Chinese journal of oncology],
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) promotes in vitro platelet aggregation.
October 2007, Hematology (Amsterdam, Netherlands),
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis.
December 1996, Clinical and experimental immunology,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF).
November 1993, The Journal of clinical endocrinology and metabolism,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from rat nasal mucosa.
September 1993, Pharmaceutical research,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis.
November 1993, Journal of internal medicine,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
[The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
September 2018, Zhonghua yi xue za zhi,
H Fukutani, and M Ogawa, and N Horikoshi, and K Inoue, and T Mukaiyama, and D Nagamine, and K Shinagawa, and M Tabata, and A Hirano, and N Mizunuma
Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on allogeneic bone marrow transplantation in mice.
May 1990, The Tokai journal of experimental and clinical medicine,
Copied contents to your clipboard!